The funds will be used to conduct studies on Iantrek’s Micro-Interventional Glaucoma Surgical devices in the U.S.
Iantrek is the only glaucoma surgical company with FDA-registered technology to target outflow pathways.
“There remains a significant unmet clinical need to provide safe and effective micro-interventional tools for aqueous outflow management,” Sean Ianchulev, MD, Iantrek’s founder and CEO, said in an Aug. 30 press release. “We are grateful to have a world-class syndicate of investors supporting our efforts to advance these new technologies. With two commercial ready [Micro-Interventional Glaucoma Surgical] platforms, Iantrek is uniquely positioned to transform the horizon of micro-interventional ophthalmic surgery.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
